Literature DB >> 26077666

Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy.

Kiyoko Kawamura1, Akihiko Wada1,2, Ji-Yang Wang3,4, Quanhai Li1,5, Akihiro Ishii6, Hideki Tsujimura6, Toshiyuki Takagi6, Makiko Itami7, Yuji Tada2, Koichiro Tatsumi2, Hideaki Shimada8, Kenzo Hiroshima9, Masatoshi Tagawa10,11.   

Abstract

PURPOSE: Activation-induced cytidine deaminase (AID) is involved in somatic hypermutation and class switch recombination processes in the antibody formation. The AID activity induces gene mutations and could be associated with transformation processes of B cells. Nevertheless, the relation between AID expression and the prognosis of B cell lymphoma patients remains uncharacterized.
METHODS: We examined expression levels of the AID gene in 89 lymph node specimens from lymphoma and non-lymphoma patients with Northern blot analysis and investigated an association with their survival.
RESULTS: The AID gene was preferentially expressed in B cell lymphoma in particular in diffuse large B cell lymphoma and follicular lymphoma. We confirmed AID protein expression in the mRNA-positive but not in the negative specimens with Western blot analysis and immunohistochemical staining. Survival of the patients treated with cyclophosphamide-/doxorubicin-/vincristine-/prednisone-based chemotherapy demonstrated that the prognosis of diffuse large B cell patients was unfavorable in the mRNA-positive group compared with the negative group, and that AID expression levels were correlated with the poor prognosis. In contrast, AID expression was not linked with the prognosis of follicular lymphoma patients.
CONCLUSIONS: AID expression is a predictive marker for an unfavorable outcome in DLBCL patients treated with the chemotherapy.

Entities:  

Keywords:  Activation-induced cytidine deaminase; Diffuse large B cell lymphoma; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26077666     DOI: 10.1007/s00432-015-2001-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

Review 1.  Linking class-switch recombination with somatic hypermutation.

Authors:  K Kinoshita; T Honjo
Journal:  Nat Rev Mol Cell Biol       Date:  2001-07       Impact factor: 94.444

2.  Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming.

Authors:  Hugh D Morgan; Wendy Dean; Heather A Coker; Wolf Reik; Svend K Petersen-Mahrt
Journal:  J Biol Chem       Date:  2004-09-24       Impact factor: 5.157

3.  AID mutant analyses indicate requirement for class-switch-specific cofactors.

Authors:  Van-Thanh Ta; Hitoshi Nagaoka; Nadia Catalan; Anne Durandy; Alain Fischer; Kohsuke Imai; Shigeaki Nonoyama; Junko Tashiro; Masaya Ikegawa; Satomi Ito; Kazuo Kinoshita; Masamichi Muramatsu; Tasuku Honjo
Journal:  Nat Immunol       Date:  2003-08-10       Impact factor: 25.606

4.  Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression.

Authors:  Toshiyuki Morisawa; Hiroyuki Marusawa; Yoshihide Ueda; Akio Iwai; Il-mi Okazaki; Tasuku Honjo; Tsutomu Chiba
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

5.  Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype.

Authors:  Laura A Smit; Richard J Bende; Jan Aten; Jeroen E J Guikema; Wilhelmina M Aarts; Carel J M van Noesel
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

6.  AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations.

Authors:  Mona Leuenberger; Simona Frigerio; Peter J Wild; Franziska Noetzli; Dimitri Korol; Dieter R Zimmermann; Carole Gengler; Nicole M Probst-Hensch; Holger Moch; Marianne Tinguely
Journal:  Mod Pathol       Date:  2009-11-06       Impact factor: 7.842

7.  Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes.

Authors:  Keigo Machida; Kevin T-N Cheng; Vicky M-H Sung; Shigetaka Shimodaira; Karen L Lindsay; Alexandra M Levine; Ming-Yang Lai; Michael M C Lai
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-03       Impact factor: 11.205

8.  Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation.

Authors:  Pablo Oppezzo; Françoise Vuillier; Yuri Vasconcelos; Gérard Dumas; Christian Magnac; Beatrice Payelle-Brogard; Otto Pritsch; Guillaume Dighiero
Journal:  Blood       Date:  2003-01-09       Impact factor: 22.113

9.  Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).

Authors:  P Revy; T Muto; Y Levy; F Geissmann; A Plebani; O Sanal; N Catalan; M Forveille; R Dufourcq-Labelouse; A Gennery; I Tezcan; F Ersoy; H Kayserili; A G Ugazio; N Brousse; M Muramatsu; L D Notarangelo; K Kinoshita; T Honjo; A Fischer; A Durandy
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

Review 10.  Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer.

Authors:  Diana Mechtcheriakova; Martin Svoboda; Anastasia Meshcheryakova; Erika Jensen-Jarolim
Journal:  Cancer Immunol Immunother       Date:  2012-04-19       Impact factor: 6.968

View more
  4 in total

1.  Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3B.

Authors:  Justin J King; Faezeh Borzooee; Junbum Im; Mahdi Asgharpour; Atefeh Ghorbani; Cody P Diamond; Heather Fifield; Lesley Berghuis; Mani Larijani
Journal:  ACS Pharmacol Transl Sci       Date:  2021-07-19

2.  Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.

Authors:  Pablo Elías Morande; Mariela Sivina; Angimar Uriepero; Noé Seija; Catalina Berca; Pablo Fresia; Ana Inés Landoni; Javier M Di Noia; Jan A Burger; Pablo Oppezzo
Journal:  Blood       Date:  2019-02-27       Impact factor: 25.476

3.  The uracil-DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID.

Authors:  Shiva Safavi; Ariane Larouche; Astrid Zahn; Anne-Marie Patenaude; Diana Domanska; Kiersten Dionne; Torbjørn Rognes; Felix Dingler; Seong-Kwi Kang; Yan Liu; Nathalie Johnson; Josée Hébert; Ramiro E Verdun; Cristina A Rada; Francisco Vega; Hilde Nilsen; Javier M Di Noia
Journal:  NAR Cancer       Date:  2020-08-27

4.  HIV-1 Tat Activates Akt/mTORC1 Pathway and AICDA Expression by Downregulating Its Transcriptional Inhibitors in B Cells.

Authors:  Burkitkan Akbay; Diego Germini; Amangeldy K Bissenbaev; Yana R Musinova; Evgeny V Sheval; Yegor Vassetzky; Svetlana Dokudovskaya
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.